Treating Painful Diabetic Peripheral Neuropathy: An Update

MATTHEW J. SNYDER, DO, and LAWRENCE M. GIBBS, MD, Saint Louis University Family Medicine Residency, Belleville, Illinois
TAMMY J. LINDSAY, MD, Saint Louis University Family Medicine Residency, St. Louis, Missouri

Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who are treated in the office setting and significantly affects quality of life. It typically causes burning pain, paresthesias, and numbness in a stocking-glove pattern that progresses proximally from the feet and hands.Clinicians should carefully consider the patient’s goals and functional status and potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the only medications approved by the U.S. Food and Drug Administration for treating this disorder. Based on current practice guidelines, these medications, with gabapentin and amitriptyline, should be considered for the initial treatment. Second-line therapy includes opioid-like medications (tramadol and tapentadol), venlafaxine, desvenlafaxine, and topical agents (lidocaine patches and capsaicin cream). Isosorbide dinitrate spray and transcutaneous electrical nerve stimulation may provide relief in some patients and can be considered at any point during therapy. Opioids and selective serotonin reuptake inhibitors are optional third-line medications. Acupuncture, traditional Chinese medicine, alpha lipoic acid, acetyl-L-carnitine, primrose oil, and electromagnetic field application lack high-quality evidence to support their use. (Am Fam Physician. 2016;94(3):227-234. Copyright © 2016 American Academy of Family Physicians.)

Painful diabetic peripheral neuropathy (DPN) occurs in approximately 30% of patients with diabetes mellitus who are hospitalized and in 25% of patients with diabetes who are treated in the office setting.\(^1\) It develops as a late manifestation of uncontrolled or long-standing diabetes.\(^1\) As many as 12% of patients with painful DPN do not report symptoms, and 39% of patients with the disorder do not receive any treatment.\(^2\)

Distal symmetric polyneuropathy, which is characterized by burning pain, paresthesias, and numbness that follows a stocking-glove pattern and progresses proximally, occurs in approximately 26% of patients with DPN. Less than 20% of patients with diabetes experience dynamic mechanical allodynia (pain in response to stroking lightly), thermal hyperalgesia (increased sensitivity to pain by thermal stimuli), or pain attacks. Poorly controlled blood glucose levels, especially greater variation in glucose levels, contribute to the occurrence and severity of painful DPN.\(^3\) A 2012 Cochrane review of two randomized controlled trials (RCTs; n = 1,228) found that enhanced glucose control in patients with type 1 diabetes significantly reduced the risk of developing DPN (risk difference = 1.84%; 95% confidence interval [CI], \(-1.11\) to \(-2.56\)). A similar analysis of four RCTs in patients with type 2 diabetes, however, did not show a statistically significant reduction in the rate of DPN with enhanced glucose control.\(^4\) Cardiovascular risk factors, including age, tobacco use, hypertension, obesity, dyslipidemia, and peripheral artery disease, are also associated with an increased risk of painful DPN.\(^1\)

Pharmacologic and nonpharmacologic interventions are available for the treatment of painful DPN. However, there are few high-quality, head-to-head clinical trials comparing these therapeutic approaches, and because the available studies use varying methodologies, it is difficult to know which treatment strategy may be most effective.

Pharmacologic Treatment Options

Only two medications, pregabalin (Lyrica) and duloxetine (Cymbalta), have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of DPN.
Guidelines from national organizations such as the American Academy of Neurology, however, recommend the use of a broader range of medications.

Clinicians should consider the patient’s age, health-related quality-of-life goals, physical function, and comorbidities, as well as the possible adverse effects of medication use, in the management of pharmacologic therapy. Additionally, medication dosages and the duration of therapy should be regulated and titrated based on regular patient feedback regarding pain relief, improved function, and adverse effects.1

Figure 1 presents a treatment algorithm for painful DPN based on available evidence.1,3,5–8 Selected medications and their dosages, costs, and numbers needed to treat (NNTs) are presented in Table 1.1,7,9–14 Table 2 lists common adverse effects of medications used to treat painful DPN.1,3,12,13,15 Common drug interactions are described in Table 3.16

**ANTICONVULSANTS**

Anticonvulsants, including topiramate (Topamax), valproate (Depacon), oxcarbazepine (Trileptal), lamotrigine (Lamictal), and lacosamide (Vimpat), as well as the newer calcium channel alpha-2-delta ligand class anticonvulsants (gabapentin [Neurontin] and pregabalin), have been studied for the treatment of painful DPN. Based on a recent meta-analysis, both the American Academy of Neurology and Toronto guidelines recommend pregabalin as the first-line medication for painful DPN, with gabapentin as the first-line alternative.3

Pregabalin provides consistent pain relief based on a dose-dependent response compared with placebo. A meta-analysis of seven RCTs (n = 1,596) comparing pregabalin with placebo showed that dosages of 300 mg daily and 600 mg daily (or divided twice daily) resulted in greater than 50% pain reduction in 39% and 47% of patients, respectively, vs. 22% with placebo. Onset of action occurred at five days with 300 mg and at four days with 600 mg. Dosing at 150 mg daily was ineffective.1,3

Common adverse reactions to pregabalin (Table 2)1,3,12,13,15 produced discontinuation rates of 9.8% (300 mg) and 14.6% (600 mg).1

**Management of Painful Diabetic Peripheral Neuropathy**

**Initial evaluation**
- Rule out other causes of neuropathy*
- Establish treatment goals
- Optimize glycemic control

**First-line therapy**
- Anticonvulsants
- Antidepressants (TCAs and SNRIs)
- Pregabalin† (Lyrica)
- Gabapentin (Neurontin)
- Duloxetine (Cymbalta)

**Second-line therapy**
- Opioid-like drugs
- Topical treatments
- SNRIs§
  - Venlafaxine
  - Desvenlafaxine (Pristiq)
- Tramadol||
- Tapentadol ER (Nucynta ER)
- Lidocaine 5% patch
- Capsaisin 0.075% cream

**Third-line therapy**
- SSRIs
  - Citalopram (Celexa)
  - Paroxetine (Paxil)
- Escitalopram (Lexapro)
- Opioids¶
  - Oxycodone controlled release

May consider adding at any time:
- Isosorbide dinitrate spray (30 mg applied to the bottom of feet before bedtime)
- Transcutaneous electrical nerve stimulation

ER = extended release; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

*—Other causes of neuropathy include malignancy, alcohol use, human immunodeficiency virus infection, isoniazid use, and chemotherapy.

†—Pregabalin should be used cautiously in patients with heart failure and in persons concomitantly using thiazolidinediones, because cases of decompensated heart failure with pregabalin use have been reported.1 In addition, renal insufficiency (creatinine clearance ≤ 30 mL per minute per 1.73 m² [0.50 mL per second per m²]) requires dose adjustment.1

§—Amitriptyline is the only TCA with good evidence of benefit for treating diabetic neuropathy. TCAs should also be used cautiously and should generally be avoided in older adults because of adverse anticholinergic effects.

||—Tramadol lowers the seizure threshold and should be avoided in patients with epilepsy or in those at risk of seizures.7

¶—Opioids should be used with caution because long-term use is associated with numerous adverse effects and increased morbidity and mortality. If opioids are used, oxycodone is commonly prescribed, but alternatives include methadone, levophanol, and morphine.

**Figure 1. Algorithm for the management of painful diabetic peripheral neuropathy.**

Information from references 1 through 3, and 5 through 8.
Pregabalin had similar effectiveness to amitriptyline in relieving painful DPN with fewer adverse events (18% vs. 43%, $P < .0001$). Health-related quality-of-life measures including social functioning, mental health, bodily pain, and vitality all improved, and sleep interference decreased with pregabalin administration.\textsuperscript{2,3}

Gabapentin at dosages of 1,200 mg daily or greater is more effective than placebo and has been shown to have an effect similar to pregabalin (8% to 13% reduction in symptoms) based on nine RCTs ($n = 1,604$). Compared with amitriptyline, similar effectiveness was noted in at least five RCTs.

Pregabalin is preferred to gabapentin as a first-line medication because of the availability of higher-quality studies on its effects, more predictable pharmacokinetics, shorter titration periods, the option for twice-daily dosing, and no dosing adjustment requirement in patients with renal impairment. Nonetheless, gabapentin has few

---

**Table 1. Medications for the Treatment of Painful Diabetic Peripheral Neuropathy**

<table>
<thead>
<tr>
<th>Medication*</th>
<th>Initial dosage</th>
<th>Maximum dosage</th>
<th>Cost†</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticonvulsants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregabalin (Lyrica)</td>
<td>300 mg divided twice daily</td>
<td>600 mg divided twice daily</td>
<td>NA ($370)</td>
<td>NNT = 5 to 8, NNH = 9 to 16\textsuperscript{‡}</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>1,200 mg divided three times daily</td>
<td>3,600 mg divided three times daily</td>
<td>$10 ($330)</td>
<td>NNT = 3, NNH = 4\textsuperscript{‡}</td>
</tr>
<tr>
<td><strong>Tricyclic antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>10 mg daily at bedtime</td>
<td>150 mg daily at bedtime or divided twice daily</td>
<td>$14 (NA)</td>
<td>NNT = 1 to 3, NNH = 28 (major adverse events), 6 (minor adverse events)\textsuperscript{‡}</td>
</tr>
<tr>
<td><strong>Serotonin-norepinephrine reuptake inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine (Cymbalta)</td>
<td>60 mg daily or divided twice daily</td>
<td>120 mg daily or divided twice daily</td>
<td>$32 ($240)</td>
<td>NNT = 5, NNH = 17\textsuperscript{‡}</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>150 mg daily</td>
<td>225 mg daily</td>
<td>$14 ($322)</td>
<td>NNT = 3, NNH = 16</td>
</tr>
<tr>
<td>Desvenlafaxine (Pristiq)</td>
<td>200 mg daily</td>
<td>400 mg daily</td>
<td>NA ($560)</td>
<td>NNT = 9, NNH = 6 to 14\textsuperscript{‡}</td>
</tr>
<tr>
<td><strong>Opioid-like medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>50 mg every 4 to 6 hours</td>
<td>100 mg every 6 hours (maximum 400 mg per day)</td>
<td>$8 (NA)</td>
<td>NNT = 4, NNH = 8</td>
</tr>
<tr>
<td>Tapentadol ER (Nucynta ER)</td>
<td>100 mg twice daily</td>
<td>250 mg twice daily</td>
<td>NA ($520)</td>
<td>NNT = 9 to 10, NNH = 5\textsuperscript{‡}</td>
</tr>
<tr>
<td><strong>Topical medications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lidocaine 5% patch</td>
<td>1 patch daily</td>
<td>3 patches daily</td>
<td>$240 (NA)</td>
<td>NNT = 4</td>
</tr>
<tr>
<td>Capsaicin 0.075% cream</td>
<td>Four times daily</td>
<td>NA</td>
<td>NA ($22 per 55-g tube)</td>
<td>NNT = 7</td>
</tr>
<tr>
<td>Isosorbide dinitrate spray</td>
<td>30 mg at bedtime applied to bottom of feet</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Selective serotonin reuptake inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram (Celexa)</td>
<td>10 mg daily</td>
<td>40 mg daily</td>
<td>$6 ($215)</td>
<td>NNT = 7</td>
</tr>
<tr>
<td>Paroxetine (Paxil)</td>
<td>10 mg daily</td>
<td>40 mg daily</td>
<td>$9 ($170)</td>
<td>NNT = 7</td>
</tr>
<tr>
<td>Escitalopram (Lexapro)</td>
<td>10 mg daily</td>
<td>20 mg daily</td>
<td>$9 ($250)</td>
<td>NNT = 7</td>
</tr>
<tr>
<td><strong>Opioids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone controlled release§</td>
<td>10 mg twice daily</td>
<td>40 mg twice daily</td>
<td>$175 (NA)</td>
<td>NNT = 6, NNH = 13</td>
</tr>
</tbody>
</table>

---

*—Listed in order of category and recommended use.
‡—Varies in dose-dependent fashion.
§—If opioids are used, oxycodone is commonly prescribed, but other agents, including methadone, levorphanol, and morphine, may be considered. Most studies of opioids for treating neuropathic pain are short-term studies; benefit from long-term use is less certain.

Information from references 1, 7, and 9 through 14.
drug interactions and is the less expensive generic option.\textsuperscript{1,3} Compared with pregabalin, which improves numerous quality-of-life measures, the only quality-of-life measures improved with gabapentin are mental health and vitality.\textsuperscript{2}

Few high-quality studies have investigated the effectiveness of valproate, topiramate, carbamazepine (Tegretol), oxcarbazepine, lamotrigine, and lacosamide. Thus, these agents are not recommended for the treatment of painful DPN.\textsuperscript{2,17}

**TRICYCLIC ANTIDEPRESSANTS**

Amitriptyline is an effective first-line medication for younger adults.\textsuperscript{1,3} A 2011 systematic review of three RCTs studied the effects of amitriptyline vs. placebo in patients with painful DPN. Amitriptyline had 43% more responders (at least 20% pain reduction) than placebo, reducing pain by 58% to 63% on a five-point pain scale.\textsuperscript{2} Lower-quality evidence from a 2015 Cochrane review of four RCTs including 382 patients with all causes of neuropathic pain showed that amitriptyline use led to a statistically significant benefit (relative risk = 2.0; 95% CI, 1.5 to 2.8; NNT = 5).\textsuperscript{18} Health-related quality-of-life outcomes were not studied.

Despite its potential for benefit, amitriptyline is associated with significant adverse anticholinergic effects in up to one-third of patients (Table 2\textsuperscript{3,12,13,15}), and its use should be avoided in older adults and monitored with caution in other patients. For other tricyclic antidepressants (i.e., imipramine, desipramine, and nortriptyline [Pamelor]), 11 RCTs provide insufficient high-quality evidence to determine whether they are effective treatments for painful DPN.\textsuperscript{2,19,20}

**SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS**

Duloxetine is a first-line medication that received FDA approval in 2004 for treating painful DPN.\textsuperscript{1,3,21} A 2014 Cochrane review of eight studies (n = 2,728) showed that duloxetine at 60 mg daily led to at least 50% pain reduction at 12 weeks (NNT = 5; 95% CI, 4 to 7) vs. placebo.\textsuperscript{2} Furthermore, a 2011 multicenter RCT (n = 272) showed duloxetine

---

**Table 2. Adverse Effects of Medications Commonly Used to Treat Painful Diabetic Peripheral Neuropathy**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adverse effect</th>
<th>Patients experiencing adverse effect (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin (Lyrica)</td>
<td>Somnolence</td>
<td>5 to 40</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>5 to 38</td>
</tr>
<tr>
<td></td>
<td>Peripheral edema</td>
<td>4 to 17</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>2 to 13</td>
</tr>
<tr>
<td></td>
<td>Weight gain &gt; 7%</td>
<td>5</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>Somnolence</td>
<td>22 to 48</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>22 to 28</td>
</tr>
<tr>
<td></td>
<td>Weight gain &gt; 7%</td>
<td>5</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Dry mouth</td>
<td>2 to 89</td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>11 to 34</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>11 to 21</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>5 to 16</td>
</tr>
<tr>
<td>Serotonin-norepinephrine reuptake inhibitors</td>
<td>Nausea</td>
<td>10 to 32</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>8 to 28</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>6 to 25</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>7 to 19</td>
</tr>
<tr>
<td></td>
<td>Dyspepsia</td>
<td>9 to 18</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Constipation</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Drowsiness</td>
<td>30</td>
</tr>
<tr>
<td>Tapentadol ER (Nucynta ER)</td>
<td>Nausea</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Restlessness</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>10</td>
</tr>
<tr>
<td>Lidocaine 5% patch</td>
<td>No adverse effect significantly different from placebo</td>
<td>—</td>
</tr>
<tr>
<td>Capsaicin 0.075% cream</td>
<td>Burning at application site</td>
<td>54 to 63</td>
</tr>
<tr>
<td>Opioids</td>
<td>Constipation</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Drowsiness</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Hyperalgesia</td>
<td>&lt; 20</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>12</td>
</tr>
</tbody>
</table>

ER = extended release.

Information from references 3, 12, 13, and 15.
Diabetic Peripheral Neuropathy

August 1, 2016 • Volume 94, Number 3 • www.aafp.org/afp

American Family Physician 231

at 60 mg daily to be noninferior to pregabalin at 300 mg daily in patients with an inadequate pain response to treatment with gabapentin over a 12-week period.22 Duloxetine has also been shown to be effective and tolerable in the management of painful DPN in older adults.23 Other serotonin-norepinephrine reuptake inhibitors (SNRIs) that are used for the treatment of painful DPN include venlafaxine and desvenlafaxine (Pristiq). Although they are considered second-line medications, these SNRIs are often better tolerated and have fewer drug interactions than amitriptyline, one of the first-line medications.

A 2004 trial showed that higher doses of venlafaxine (150 to 225 mg) led to greater improvements in pain scores than placebo.24 A 2007 Cochrane review of three studies of venlafaxine for general neuropathic pain showed an NNT of 3 (95% CI, 2.2 to 5.1).10 A 2014 RCT (n = 412) showed desvenlafaxine at dosages of 200 and 400 mg daily to be more effective than placebo in relieving pain associated with DPN, based on a decrease

<table>
<thead>
<tr>
<th>Medication</th>
<th>Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin (Lyrica) and gabapentin (Neurontin)</td>
<td>May increase toxic effects of CNS depressants,* SSRIs, thiazolidinediones Toxic effects may be increased by CNS depressants,* AcCHS inhibitors, hydroxyzine, and magnesium sulfate</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>May increase toxic effects of CNS depressants,* QTc-prolonging agents,† SSRIs, St. John’s wort, sulfonylureas, tramadol, and warfarin (Coumadin) Effectiveness can be decreased by St. John’s wort, AcCHS inhibitors, and carbamazepine (Tegretol) Toxic effects may be increased by CNS depressants,* QTc-prolonging agents,† SSRIs, St. John’s wort, antiemetics (e.g., 5-HT3 antagonists, ondansetron [Zofran]), antipsychotic agents, and bupropion (Wellbutrin) Absolutely contraindicated with MAO inhibitors</td>
</tr>
<tr>
<td>Duloxetine (Cymbalta)</td>
<td>May increase toxic effects of CNS depressants,* antiplatelet agents, alpha and beta agonists, anticoagulants (e.g., warfarin), antipsychotic agents Absolutely contraindicated with MAO inhibitors May decrease effects of TCAs and linezolid (Zyvox) Toxic effects may be increased by CNS depressants,* alcohol, antiemetics (e.g., 5-HT3 antagonists, ondansetron), antipsychotic agents, metoclopramide (Reglan) Effectiveness may be decreased by CYP1A2 inducers‡</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>May increase toxic effects of CNS depressants* and SSRIs May decrease effectiveness of alpha-2 agonists Absolutely contraindicated with MAO inhibitors and linezolid Toxic effects may be increased by CNS depressants,* CYP2D6 inhibitors,§ CYP3A4 inhibitors,‖ and SSRIs</td>
</tr>
<tr>
<td>Tramadol</td>
<td>May increase toxic effects of CNS depressants* and SSRIs Toxic effects may be increased by CNS depressants,* SSRIs, and TCAs</td>
</tr>
<tr>
<td>Tapentadol ER (Nucynta ER)</td>
<td>Absolutely contraindicated with MAO inhibitors and mixed agonist and antagonist opioids May increase toxic effects of CNS depressants,* diuretics, and desmopressin Toxic effects may be increased by alcohol, amphetamines, anticholinergic agents, and magnesium sulfate</td>
</tr>
<tr>
<td>Opioids (oxycodone controlled release)</td>
<td>May increase toxic effects of CNS depressants,* MAO inhibitors, and SSRIs Effectiveness of medication can be increased by CYP3A4 inducers¶ Toxic effects may be increased by CNS depressants*</td>
</tr>
</tbody>
</table>

AcCHS = acetylcholinesterase; CNS = central nervous system; CYP = cytochrome P450; ER = extended release; MAO = monoamine oxidase; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

*—Opioids, zolpidem (Ambien), pregabalin, gabapentin, TCAs, and tramadol.
†—Amiodarone, azithromycin (Zithromax), clarithromycin (Biaxin), fluoxetine (Prozac), haloperidol, risperidone (Risperdal), and sotalol (Betapace).
‡—Carbamazepine, phenobarbital, and rifampin.
§—Amiodarone, celecoxib (Celebrex), cimetidine (Tagamet), clomipramine (Anafranil), desipramine, duloxetine, haloperidol, imipramine, isoniazid, ketoconazole, lidocaine, methadone, pioglitazone (Actos), and sertraline (Zoloft).
‖—Amiodarone, cimetidine, clotrimazole, cyclosporine (Sandimmun), desipramine, diltiazem, efavirenz (Sustiva), erythromycin, fluconazole (Diflucan), grapefruit juice, haloperidol, metronidazole (Flagyl), sertraline, tetracycline, and verapamil.
¶—Carbamazepine, dexamethasone, efavirenz, fosphenytoin (Cerebyx), phenytoin (Dilantin), and St. John’s wort.

Information from reference 16.
Diabetic Peripheral Neuropathy

12 studies supporting evidence; B = inconsistent or evidence; C = consensus, of three

References

response) to that of pregabalin (66.7% vs. 69.1%; one

ment resulted in comparable pain relief (30% to 50%

Lidocaine 5% patch or medicated plaster treat

duced at any time as an adjunctive treatment.

DPN in one small RCT of 22 patients.

Isosorbide dinitrate is a vasodilator and

ISOSORBIDE DINITRATE SPRAY

for the treatment of painful DPN.

and capsaicin 0.075% cream should also be considered

Isosorbide dinitrate spray, lidocaine 5% patch or plaster,

Topical Medications

Isosorbide dinitrate spray, lidocaine 5% patch or plaster,

and capsaicin 0.075% cream should also be considered

for the treatment of painful DPN.2

ISOSORBIDE DINITRATE SPRAY

Isosorbide dinitrate is a vasodilator and smooth-muscle relaxant that produced an 18% pain score reduction when sprayed on the skin of areas affected by painful DPN in one small RCT of 22 patients.2,27 It can be introduced at any time as an adjunctive treatment.

LIDOCAINE

Lidocaine 5% patch or medicated plaster treatment resulted in comparable pain relief (30% to 50% response) to that of pregabalin (66.7% vs. 69.1%; one RCT, n = 204). Greater improvement in quality-of-life scores and fewer adverse effects occurred in the lidocaine group than in the pregabalin group.28

CAPSAICIN

Treatment with capsaicin 0.075% cream applied to the painful area four times daily resulted in significant pain relief (50% pain reduction; odds ratio [OR] = 2.37; 95% CI, 1.32 to 4.26) but also adverse events that led to withdrawal from the study (OR = 4.02; 95% CI, 1.45 to 11.06).27 A 2014 systematic review of three RCTs revealed the superiority of capsaicin 0.075% to placebo (standardized mean deviation [SMD] = 0.91; 95% credible interval [CrI], −1.18 to −0.08, large), but not to tricyclic antidepressants (SMD = −0.13; 95% CrI, −1.03 to 0.74, small) or SNRIs (SMD = 0.45; 95% CrI, −0.49 to 1.36, small).19 The primary adverse effect is burning at the application site, which improves with longer duration of treatment.

Other concentration levels and combination treatments have also been studied. Notably, combining capsaicin 0.025% with doxepin 3.3% led to decreased skin irritation compared with capsaicin alone (one RCT, n = 200, 61% vs. 81% reduction in skin irritation).29

Alternative Medications

SELECTIVE SEROTONIN REUPTAKE INHIBITORS

Selective serotonin reuptake inhibitors are considered third-line medications for treatment of painful DPN because of a lack of high-quality studies supporting their benefit.3 Citalopram (Celexa), paroxetine (Paxil), and escitalopram (Lexapro) appear to be mildly effective for treating painful DPN, whereas fluoxetine (Prozac) does not. Combined data from four small studies reveal an NNT of 7 for pain reduction with this class of medications.30

OPIOIDS

Despite concerns about dependency and lower-quality evidence for the benefit of chronic opioid therapy for nonmalignant pain,12 guidelines suggest a possible

232 American Family Physician www.aafp.org/afp Volume 94, Number 3 • August 1, 2016

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregabalin (Lyrica), gabapentin (Neurontin), amitriptyline (except in older adults), or duloxetine (Cymbalta) should be used as first-line treatment for painful diabetic peripheral neuropathy.</td>
<td>A</td>
<td>1-3, 8, 9, 22</td>
</tr>
<tr>
<td>The serotonin-norepinephrine reuptake inhibitors venlafaxine and desvenlafaxine (Pristiq) and opioid-like medications (tramadol and extended-release tapentadol [Nucynta ER]) may be considered if first-line medications do not provide adequate pain relief.</td>
<td>A</td>
<td>1-3, 6, 8-11</td>
</tr>
<tr>
<td>Lidocaine 5% patch, capsaicin 0.075% cream, isosorbide dinitrate spray, and transcutaneous electrical nerve stimulation can be added to therapy for painful diabetic peripheral neuropathy.</td>
<td>B</td>
<td>2, 8, 15, 27, 40</td>
</tr>
</tbody>
</table>

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.
benefit for patients with painful DPN.\textsuperscript{2,5,31} However, monotherapy with opioids is not a first-line treatment and should be reserved for patients who do not achieve pain relief goals and functional improvement with other therapies.\textsuperscript{2,5} Notably, most studies on the use of opioids for neuropathic pain are short-term studies.\textsuperscript{14} Chronic opioid use leads to tolerance and hyperalgesia.\textsuperscript{32}

A 2013 Cochrane review of 14 RCTs (n = 845, 12-week duration or less) analyzed the use of opioids for general neuropathic pain. The review evaluated the effectiveness of methadone, levorphanol, morphine, and controlled-release oxycodone and found that opioids demonstrated superior pain relief compared with placebo (greater than 33% pain relief = 57% vs. 34%; NNT = 4; 95% CI, 2.7 to 7.7; greater than 50% pain relief = 47% vs. 30%; NNT = 6; 95% CI, 3.0 to 50.0).\textsuperscript{12} Treatment with opioids did not, however, result in improvement in many aspects of emotional or physical functioning, as measured by various validated questionnaires. In contrast, a 2014 Cochrane review assessing the use of controlled-release oxycodone (three studies, n = 204) in the treatment of painful DPN found insufficient evidence to support its role in therapy.\textsuperscript{33}

### Other Treatments

#### ACUPUNCTURE

Acupuncture, which has been the focus of 75 low-quality RCTs; traditional Chinese medicine, which typically includes acupuncture and herbal medicine; and electromagnetic field application are not currently recommended for the treatment of painful DPN because large, high-quality RCTs are lacking.\textsuperscript{2,34-36}

#### ALPHA LIPOIC ACID

Alpha lipoic acid is an antioxidant substance that has been studied for treatment of neuropathic pain. Based on a 2012 meta-analysis (n = 448), alpha lipoic acid (600 mg) administered intravenously daily for three weeks led to a decrease in reported neuropathic pain for up to one year (standardized mean symptom score reduction = −2.81; 95% CI, −4.16 to −1.46, \( P = .0001 \)). However, studies investigating long-term clinical improvement are lacking. Oral administration did not produce a clinically significant symptom score reduction.\textsuperscript{1,37}

#### ACETYL-L-CARNITINE

Acetyl-l-carnitine, based on a 2008 meta-analysis of two RCTs (n = 1,679), and primrose oil, based on three small RCTs, demonstrated an improvement in nerve conduction but a lack of clinically significant long-term improvement in symptom scores.\textsuperscript{38,39}

### TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION

The results of several small studies suggest that transcutaneous electrical nerve stimulation (TENS) should be considered as a treatment for painful DPN.\textsuperscript{41} An RCT involving 31 participants showed that 15 of 18 (83%) patients receiving TENS had improved pain scores (reduction from 3.17 to 1.44 on a 5-point scale) vs. five of 13 (38%) patients receiving sham treatments (reduction from 2.98 to 2.38).\textsuperscript{42} In another small RCT (n = 19), pain scores were reduced by 27% with six weeks of TENS therapy.\textsuperscript{42} TENS can be started at any time during therapy as an adjunct to other treatments.

#### Data Sources: The primary literature search was completed with Essential Evidence Plus and included searches of the Cochrane database, PubMed, and National Guideline Clearinghouse with the terms diabetic neuropathies and diabetic neuropathy. In addition, a PubMed search was completed using the terms diabetic neuropathy pain treatment, anti-convulsants, tricyclic antidepressant, alpha lipoic acid, primrose oil, and alternative medicine. Search date: November 20, 2015.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of Saint Louis University, the U.S. Air Force Medical Service, or the U.S. Air Force at large.

This review updates a previous article on this topic by Lindsay, Rodgers, Savath, and Hettinger.\textsuperscript{41}

### The Authors

MATTHEW J. SNYDER, DO, FAAFP, is associate program director of the Saint Louis University Family Medicine Residency Program in Belleville, Ill., which is affiliated with Scott Air Force Base.

LAWRENCE M. GIBBS, MD, FAAFP, is an assistant clinical professor in the Saint Louis University Family Medicine Residency Program, Belleville.

TAMMY J. LINDSAY, MD, FAAFP, is an associate clinical professor with the Department of Family and Community Medicine at Saint Louis University, the U.S. Air Force Medical Service, or the U.S. Air Force at large.

Address correspondence to Matthew J. Snyder, DO, Saint Louis University, 180 S. Third St., Suite 400, Belleville, IL 622209 (e-mail: mdrnsnyder@gmail.com). Reprints are not available from the authors.

### REFERENCES


Diabetic Peripheral Neuropathy


